Company news

Jupiter Neurosciences, Inc. news in 2026

Jupiter Neurosciences, Inc.'s news releases, calls and decks from 2026, newest first.

View company

Jupiter Neurosciences Announces First Patient Dosed in Phase 2a RESET Trial in Parkinson’s Disease and Exploration of Strategic Options to Maximize Shareholder Value

October 6, 2026

Jupiter Neurosciences, Inc. Announces Reverse Stock Split

August 5, 2026

Jupiter Neurosciences Signs Definitive Agreement for Exclusive U.S. Rights to ALA-002 in Transaction Valued at Up to $100 Million

July 22, 2026

Jupiter Neurosciences (NASDAQ: JUNS) Signs Definitive Agreement for Exclusive U.S. Rights to ALA-002 in Transaction Valued at Up to $100 Million

July 21, 2026

Jupiter Neurosciences Strengthens Board with Appointment of Dr. Tomas J. Philipson

July 6, 2026

Jupiter Neurosciences Announces Patient Enrollment Underway in Phase 2a RESET Trial in Parkinson’s Disease

May 26, 2026

D. Boral Capital Acted as Exclusive Placement Agent to Jupiter Neurosciences, Inc. (Nasdaq: JUNS) in Connection with its ~$2 Million Registered Direct Offering

May 26, 2026

Jupiter Neurosciences Announces Closing of $2.0 Million Registered Direct Offering

May 20, 2026

Jupiter Neurosciences Announces Pricing of $2.0 Million Registered Direct Offering

May 20, 2026

Jupiter Neurosciences Secures $100M Term Sheet for Exclusive U.S. Rights to ALA-002, a Next-Generation MDMA Therapeutic from PharmAla Biotech

May 20, 2026

Jupiter Neurosciences, Inc. to Present at The Market Movers Investor Summit

May 4, 2026

Jupiter Neurosciences, Inc. to Present at Centri Capital Conference on April 14

April 12, 2026

Jupiter Neurosciences Appoints Kristopher Fishman and Sanjiv Lal to Nugevia™ Advisory Board

April 6, 2026

Jupiter Neurosciences to Present at Emerging Growth Conference on April 2

March 30, 2026

Jupiter Neurosciences to Present at BIO Investment and Growth Summit 2026

March 1, 2026

Jupiter Neurosciences Invited to Present Clinical and Commercial Progress at Investor Dinner at Mar-a-Lago

February 25, 2026

Jupiter Neurosciences Amends Yorkville Installment Provisions to Align Capital With Clinical and Commercial Execution

February 23, 2026

Jupiter Neurosciences Expands Nugevia™ Addressable Market with Focus on GLP-1 Users

January 28, 2026

Jupiter Neurosciences Presenting at the 3rd Annual DealFlow Discovery Conference

January 27, 2026

Decks in 2026